Stopping Anemia Drug May be Wiser than Reducing Dose to Normalize Hemoglobin Levels

Newswise — Discontinuing the anemia drug epoetin may be more effective than reducing the dose for normalizing potentially dangerous high hemoglobin levels in hemodialysis patients, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results provide useful information about the balance required between administering epoetin and achieving target hemoglobin levels.

Anemia is a common complication of chronic kidney disease. Treatment often involves epoetin to boost levels of hemoglobin, the component of blood that transports oxygen throughout the body. Unfortunately, epoetin can increase the risk of heart-related complications and death when used to raise kidney disease patients’ hemoglobin levels to what is considered normal in the general population. In addition, kidney disease patients often experience significant fluctuations in hemoglobin levels outside of the recommended range (10 g/dl to 12 g/dl) when using epoetin, which may have a negative impact on health.

Little information is available on the effects of reducing or discontinuing epoetin in patients who develop high hemoglobin levels. To investigate, Daniel Weiner, MD, Jose Calvo, MD (Tufts Medical Center) and their colleagues measured hemoglobin levels over a two month period in 2,789 dialysis patients who discontinued epoetin and 754 dialysis patients who reduced their epoetin dose by 20%-30% after developing high hemoglobin levels (13 g/dl or greater). They also explored individual patient characteristics associated with more precipitous drops in hemoglobin level.

Within two months, more patients who discontinued epoetin dropped below 11 g/dl (21.5% vs 10.1%) and 10 g/dl (7.2% vs 3.6%) compared with patients who reduced their epoetin dose. Reducing epoetin was associated with more frequent lowest hemoglobin levels that remained above12 g/dl (31.1% vs 62.8% of patients), a level higher than that recommended by the FDA.

While discontinuation was associated with a higher likelihood of dropping to a hemoglobin level below 10 g/dl, this occurred in relatively few individuals. Factors associated with a drop in hemoglobin level to below 10 g/dl included higher baseline epoetin dose and elevated blood markers of inflammation. After adjusting for these factors, patients who discontinued epoetin were 1.91 times more likely to have a lowest hemoglobin level below 10 g/dl. In contrast, patients who reduced epoetin were 4.41 times as likely to have a lowest hemoglobin level above 12 g/dl.

These results indicate that once a patient reaches a hemoglobin level of 13 g/dl or higher, discontinuing epoetin is more likely to lower the hemoglobin level to within the recommended range compared with reducing the dose of epoetin. However, discontinuing epoetin also increases the patient’s risk of developing a lower-than-recommended hemoglobin level, while reducing epoetin is associated with significantly increased time at a higher-than-recommended hemoglobin level.

The major limitations of the study were the use of administrative data in a retrospective fashion, and the lack of hard outcome data, including mortality.

Study co-authors include Dana Miskulin, MD, and Klemens Meyer, MD (Tufts Medical Center).

Disclosures: Dr. Weiner, Dr. Meyer, and Dr. Miskulin have received research funding from Dialysis Clinic, Inc. (DCI), where patients in the study were treated. Dr. Weiner and Dr. Meyer are medical directors of DCI units; Dr. Meyer and Dr. Miskulin receive salary support from DCI.

The article, entitled “Nadir Hemoglobin Levels after Discontinuation of Epoetin in Hemodialysis Patients” will appear online at http://cjasn.asnjournals.org on July 22, 2010, doi 10.2215/CJN.02650310.

The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, the American Society of Nephrology (ASN) is the world’s largest professional society devoted to the study of kidney disease. Comprised of 11,000 physicians and scientists, ASN continues to promote expert patient care, to advance medical research, and to educate the renal community. ASN also informs policymakers about issues of importance to kidney doctors and their patients. ASN funds research, and through its world-renowned meetings and first-class publications, disseminates information and educational tools that empower physicians.